Due to the presence of potentially sensitive information provided by women living with HIV, data have been made available upon request. This requirement was imposed by Human Research Ethics Committee of The University of Newcastle, Australia, and the Oromia Regional State Health Bureau Research Ethics Committee, Ethiopia which approved the research protocol. The data request may be submitted to the Research Centre for Generational Health and Ageing, University of Newcastle, Australia at <rcgha@newcastle.edu.au>.

Introduction {#sec005}
============

In 2017, nearly two-thirds of the 25.7 million people living with human immunodeficiency virus (HIV) in sub-Saharan Africa (SSA) were women \[[@pone.0237212.ref001], [@pone.0237212.ref002]\], with similar proportions identified in Ethiopia \[[@pone.0237212.ref003]\]. The 2015 World Health Organization (WHO) guideline states there should be no criterion barrier in the initiation of antiretroviral therapy (ART) \[[@pone.0237212.ref004]\] which helped with reductions in HIV-related morbidity and mortality \[[@pone.0237212.ref005]\]. With the current ART expansion, meeting contraceptive needs is crucial to not only achieving fertility goals \[[@pone.0237212.ref006]\] but also reductions in maternal mortality \[[@pone.0237212.ref007]--[@pone.0237212.ref009]\], child mortality and children who are being orphaned \[[@pone.0237212.ref009]\]. Contraception could also play a critical role in the prevention of mother to child transmission of HIV (PMTCT) \[[@pone.0237212.ref010]\] because it averts unintended births \[[@pone.0237212.ref011]\]. Therefore, strengthening contraceptive programs could play a role in ending the epidemics of acquired immunodeficiency syndrome (AIDS) by 2030 (the Sustainable Development Goal 3.3) \[[@pone.0237212.ref012]\].

Despite the benefits of contraception, there are considerable contraceptive use gaps amongst women living with HIV (WLHIV) \[[@pone.0237212.ref013], [@pone.0237212.ref014]\], particularly in SSA. With high rates of unintended pregnancy \[[@pone.0237212.ref011]\] and abortion \[[@pone.0237212.ref015]\], there appears to be a high unmet need for contraception among WLHIV \[[@pone.0237212.ref016]\] and contraceptive failure \[[@pone.0237212.ref017]\]. According to the WHO, women with an unmet need are "those who are fecund and sexually active but are not using any method of contraception, and report not wanting any more children or wanting to delay the next child" \[[@pone.0237212.ref018]\].

With improved survival of the HIV-positive population because of ART \[[@pone.0237212.ref019], [@pone.0237212.ref020]\], WLHIV need clear reproductive life plans with ready access to contraception. Studies that have examined contraceptive practice among WLHIV have focused on married women \[[@pone.0237212.ref020], [@pone.0237212.ref021]\]. This places unmarried women who are sexually active at increased risk of unintended pregnancy due to the assumption made about sex only happening within the context of marriage (and therefore a lack of reproductive planning for these women through health services) \[[@pone.0237212.ref022]\].

While it has been advised by the WHO that WLHIV have the right to choose any contraceptive methods similar to HIV-negative women \[[@pone.0237212.ref017]\], the contraceptive choice in the presence of HIV appears more complex because WLHIV are required to balance the prevention of both unintended pregnancy and HIV transmission \[[@pone.0237212.ref023], [@pone.0237212.ref024]\].

Evidence suggests that theory-based research can explain not only contraceptive behaviors but also provide strategies for increased uptake and continuation \[[@pone.0237212.ref025]\]. In contraceptive research, the Health Belief Model (HBM) offers an important perspective whereby *modifying and enabling factors* (such as socio-demographic, structural, psychological and reproductive factors) interplay with personal perceptions and cues to action to influence the decision to use contraceptives \[[@pone.0237212.ref026]\] (see [Fig 1](#pone.0237212.g001){ref-type="fig"}). According to the HBM, there are four constructs of perceptions: (a) *perceived susceptibility* to dictate the perceived chance of pregnancy (unintended) if contraception is not used; (b) a *perceived severity* that describes consequences of getting and being pregnant amongst WLHIV which include perceptions regarding mother to child transmission of HIV; (c) *perceived benefits* of contraception which include effectiveness, dual protection, and reversibility of the methods; and (d) *perceived barriers* of contraceptive use include side effects of contraception. *Cues to action* are internal and external signals used to activate readiness to change \[[@pone.0237212.ref026]\]. There are several studies that have used the HBM to predict contraceptive utilization \[[@pone.0237212.ref027]--[@pone.0237212.ref031]\]; however, no study has used the HBM in relation to contraceptive use amongst WLHIV.

![Contraceptive behaviour of women living with HIV using the health belief model.](pone.0237212.g001){#pone.0237212.g001}

To inform policy and programs regarding the contraceptive use for sexually active WLHIV, understanding WLHIV's contraceptive use within this framework is crucial \[[@pone.0237212.ref032]\]. Therefore, the present study aimed to evaluate contraceptive use among sexually active WLHIV in western Ethiopia using the HBM as a conceptual framework.

Materials and methods {#sec006}
=====================

Study design and settings {#sec007}
-------------------------

This study used a facility-based cross-sectional survey among WLHIV in western Ethiopia. The study was conducted in East and West Wollega Zones of western Ethiopia from 19^th^ March to 22^nd^ June 2018.

Study population and sampling {#sec008}
-----------------------------

The study participants were recruited using a systematic sampling of HIV-positive women attending HIV clinics across four health facilities (two hospitals and two health centers). The recent treat-all policy meant there was no criteria barrier to starting ART \[[@pone.0237212.ref004]\], encouraging all PLHIV to commence ART immediately after HIV-positive diagnosis. To facilitate this in Ethiopia, a unique ART number is assigned to PLHIV to monitor their ART treatment and HIV management, and to coordinate care across different settings. For the recruitment process, a list of ART clients (each with a unique ART number) was obtained from the daily appointment calendar, excluding the personal identifiers of each client. Among 2,445 reproductive-age WLHIV, a systematic sampling of every second woman from each health facility was used to select study participants with selected WLHIV invited to participate in the study. All participants were contacted at a HIV clinic of the selected health institutions when they came for their ART services.

Eligibility for this analysis was restricted to non-pregnant WLHIV who reported: (a) being sexually active within the last six months at survey completion; (b) being fecund; (c) not wanting to have another child within two years \[[@pone.0237212.ref033], [@pone.0237212.ref034]\]; and (d) completed the questions on contraceptive use. As shown in [Fig 2](#pone.0237212.g002){ref-type="fig"}, among the 1,082 women who were surveyed, 360 sexually active WLHIV who met the eligibility criteria were included for analysis.

![Flow chart illustrating the eligibility process to obtain the final sample for analysis of sexually active WLHIV.](pone.0237212.g002){#pone.0237212.g002}

Data collection procedures {#sec009}
--------------------------

Data collection was conducted using a standard survey questionnaire which was developed based on the Ethiopian Demographic and Health Survey questionnaire \[[@pone.0237212.ref035]\] and guided by existing literature on contraception, as well as concepts within the HBM \[[@pone.0237212.ref026]\]. The tool was originally prepared in English and subsequently translated into the local language, Oromo. Data quality was maintained by training data collectors on the questionnaire, consenting procedures and completing surveys. To ensure validity (measuring what it aims to measure) and reliability (consistency of measurements) \[[@pone.0237212.ref036]\] of the questionnaire, the questions were mainly adapted from the Demographic and Health Survey (<https://dhsprogram.com/pubs/pdf/FR328/FR328.pdf>) \[[@pone.0237212.ref035]\] and Family Planning 2020 questionnaires (<https://www.familyplanning2020.org/>) \[[@pone.0237212.ref034]\], which were widely tested in many countries, including Ethiopia. Because of ethical and logistic reasons, a pilot study was carried out on 30 participants in the health facilities that were selected for main data collection. These women were not included the main data collection. Based on those results and feedbacks, some questions were modified (such as contraceptive use and fertility characteristics) for the main survey. The training and pilot testing were conducted for five days. Data were collected by five trained female nurses who had previous experience in data collection, and were fluent in the local language. The data collectors were never involved in the participants' care. Data collection was conducted face-to-face with mobile-based surveys. The Research Electronic Data Capture (REDCap) software \[[@pone.0237212.ref037]\] was used for data collection. Data collection was overseen by a supervisor for completeness and consistency. Furthermore, the data completeness, accuracy and consistency across the data collectors were checked in the REDcap database after transferring data to the database daily. Any concerns were further discussed during the next morning with data collectors.

Ethical considerations {#sec010}
----------------------

Ethical approval for this study was obtained from The Human Research Ethics Committee (HREC) of The University of Newcastle, Australia (H-2017-0289), and the Oromia Regional State Health Bureau Research Ethics Committee, Ethiopia (BEFO/HBISH/1-16/257). Official permission was obtained from hospitals, health centers, and respective HIV-clinics included in our study. An information statement was provided to all participants prior to obtaining informed verbal consent. To ensure informed verbal consent from participants, the data collectors read the information statement in the local language, Oromo. There are low literacy levels among women in Ethiopia, (42% of women in Ethiopia are literate) \[[@pone.0237212.ref035]\], so informed verbal consent was more appropriate and was approved by both ethics committees. In addition, it was a survey and the research involved no more than low risk \[[@pone.0237212.ref038]\]. Participants were given the opportunity to ask questions prior to the interview. The consent procedure took place in a separate private room by female nurse data collectors after WLHIV had finished their routine clinical care appointment. Participants were informed that their participation was voluntary and that they were free to decline participation or withdraw their consent at any time. It was made clear that participation in this study had no bearing on their receipt of clinical care. The participants were also informed that the survey involved some questions that they might find embarrassing or too personal and some that might cause them to worry about their reproductive health issues. Further, participants were informed that they did not have to answer any question that they did not feel comfortable with, and they could withdraw at any time or simply choose not to answer a particular question. Female nurses were prepared to provide psychological support if the need arose. Anonymised data were stored on password-protected Ipads during data collection. Data were stored on secure and password-protected computers.

Measures {#sec011}
--------

### Outcome variables (contraceptive use) {#sec012}

Participants were asked if they had done something or used any method to delay or avoid getting pregnant during the data collection period, i.e., between March and June 2018 (yes/no). Contraceptive users were asked about the method(s) used, which included: short-acting contraception (pills, condoms and injectables); long-acting reversible contraception (implants and Intra-Uterine Devices \[IUDs\]); and permanent contraception (vasectomy and tubal ligation). Simultaneous use of condoms and any other method(s) was defined as dual use for this study. Based on responses, we further created five exclusive groups of contraceptive users: (a) condom use only; (b) short-acting contraception only (pills, injectables); (c) dual use of condoms plus short-acting contraception (pills, injectables); (d) long-acting only (IUDs, implants); and (e) dual use of condom and long-acting contraception (IUDs, implants). Contraceptive continuation was also determined by the length of time the women were using the method(s) without interruption (≤12 months, \>12 to \< 36 months, and ≥ 36 months). Contraceptive users were also surveyed with respect to the following: partners' support of their contraceptive use (supportive, indifferent and not supportive); the source of the recent methods (hospital, health center, health post, private-for-profit, and non-government organization); whether there was counselling on possible side effects of contraceptives (yes/no); and whether they were informed about what to do concerning side effects (yes/no). Those women who reported not using contraception were also asked if they had intended to use contraception (yes/no).

### Explanatory factors {#sec013}

Using the HBM framework, potential predictors of contraceptive use focused on (a) modifying and enabling factors; (b) perceptions regarding conception and contraception; and (c) cues to action. The dimensions of modifying and enabling factors included a broad range of the following: (i) socio-demographic characteristics, (ii) HIV-related factors, and (iii) reproductive characteristics.

*Socio-demographic characteristics included*. the type of health facility being accessed for ART (categorized as hospitals and health centers); age (in years); marital status (categorized as married and unmarried); residence (urban and rural); schooling (no formal education, primary education, secondary education, and any post-secondary education); monthly family income (less than 1500 Ethiopian Birr, ≥ 1500 Ethiopian Birr, and don't know); and main decision-maker regarding income use (respondent, partner or joint decisions made) \[[@pone.0237212.ref035]\]. Furthermore, travel time to health facility (\<60 minutes, 60 to \<120 minutes, and ≥120 minutes) and round cost of travel (\<25 Birr, 25 to \<50 Birr, and ≥50 Birr) were also assessed.

*HIV-related factors included*. time since HIV diagnosis and time on ART in years, which were grouped into three (≤5 years, 5 to \<10 years, and ≥10 years); reported health status after ART initiation (poor/quite poor, neither good nor poor, quite good, and very good); partner tested for HIV (yes, no and don't know); and HIV status of tested partner (HIV-negative, HIV-positive and don't know). The recent CD4 count was collapsed into two groups based on previous thresholds for initiating ART (\<350 and ≥350 cells/μL) \[[@pone.0237212.ref039]\].

*Reproductive characteristics included*. number of children living in the household (no children, 1--2 children, 3 or more); number of children not living with mother at home (no children, 1 child, 2 or more); and number of children born since HIV diagnosis (no children, 1 child, 2 or more). Furthermore, pregnancy intention at conception of all live births in the last five years of these women was categorized into intended (*wanted then*), mistimed (*wanted later*) and unwanted (*not at all*). HIV status of mothers at conception in the last five years was also measured (HIV-negative, HIV-positive and not known).

Personal perceptions related to conception and contraception amongst WLHIV was measured using 30 questions as guided by existing HBM research on contraceptive use \[[@pone.0237212.ref028], [@pone.0237212.ref040]\]. Perceptions regarding (a) conception susceptibility (2 items), (b) severity (6 items), (c) contraception benefits (7 items), and (d) contraception barriers (11 items) were measured using five-point Likert scales (e.g., very unlikely to very likely, lowest to highest importance, strongly disagree to strongly agree, or similar). *Conception susceptibility* was assessed using questions about the perceived likelihood of becoming pregnant if contraception was not used and concerns of perceived difficulty if found pregnant right now (at the time of data collection). Perceptions regarding *severity* included questions on: HIV transmission to partner/respondent; HIV transmission during pregnancy; HIV transmission during childbirth; HIV transmission during breastfeeding; fear of orphaning the child; and stress if decided to have a baby. Perceptions regarding *contraceptive benefits* included questions on: long-term protection; convenience of methods; effectiveness; dual protection; ability to use discretely; reversibility; and the immediate return of menses after stopping the contraception. Perceptions regarding *contraceptive barriers* included questions on: pain related to implants/IUDs; inconvenience; frequency of visits to obtain the method; interaction with ART drugs; partner influence; weight gain; sexual interruptions; increased menstrual bleeding; cessation of menstrual bleeding; and bleeding between menses. Interaction with ART drugs; sexual interruptions; cessation of menstrual bleeding; bleeding between menses; frequency of visits to obtain the method; increased menstrual bleeding; and weight gain were recoded (from 1 to 5) for consistency across all other variables.

*The cues to action construct included four items measuring*. provider counselling; discussion with a partner about contraceptive options; media exposure to contraceptive information; and missed menses to start contraception after intercourse.

Statistical analyses {#sec014}
--------------------

The perception constructs and the cues to action construct (according to the HBM) were included in a principal component analysis (PCA) to summarize the data using Kaiser's varimax rotation method and a fixed number of factors. Eigenvalues were checked, with values greater than one essential to summarize using PCA. Sampling adequacy was then tested using Kaiser-Meyer-Olkin (KMO; with the threshold of 0.5 set for adequacy). Each of the five HBM PCA summed scores (conception susceptibility, severity, contraceptive benefits, contraceptive barriers and cues to action) were subsequently categorized into tertiles (e.g., high susceptibility, medium susceptibility and low susceptibility) \[[@pone.0237212.ref041]\].

Differences between contraceptive users and non-users were described with respect to the modifying and enabling factors as well as perceptions. Observed differences were evaluated using the Pearson chi-square (for categorical variables) and independent t-tests (for continuous variables) where applicable (level of significance at p \<0.05). Fisher's exact test was used where the Pearson chi-square was not appropriate. Following this, we initially used log-binomial regression models to obtain the prevalence ratio (PR) \[[@pone.0237212.ref042], [@pone.0237212.ref043]\], although convergence was not achieved, even when using the COPY adjustment method. As a result, Poisson regression models with robust standard errors were used to estimate prevalence ratios \[[@pone.0237212.ref042], [@pone.0237212.ref043]\]. Poisson regression models were initially used to identify potential factors associated with contraceptive use. Variables that were considered potential independent risk factors from the univariate analyses (p-value\<0.2) were considered for a final multivariable model, to control for confounding. The strength of the association between the outcome variable and independent variables was expressed in PR with a 95% confidence interval (CI). All analyses were conducted using STATA^®^, version 14 (Stata Corporation, College Station, TX, USA).

Results {#sec015}
=======

Socio-demographic characteristics {#sec016}
---------------------------------

Among 360 sexually active WLHIV who were included in this study, contraceptive use was reported by 270 (75.0%) participants with a total unmet need of 25.0%. The mean age of the study participants was 31.7 years. Two hundred and ninety one (80.8%) participants were married. The majority of the participants (60.0%) had a follow-up in hospitals for ART. The proportion of women who reported a monthly family income of less than 1,500 Ethiopian Birr was 52.2%. Regarding the decision-making on the utilization of their income, 36.7% of participants reported that they could decide on income jointly with their partner. There were significant differences between contraceptive users and non-users with respect to health facility, age, marital status, monthly family income, and decision-making regarding income use (see [Table 1](#pone.0237212.t001){ref-type="table"}).

10.1371/journal.pone.0237212.t001

###### Characteristics of sexually active women living with HIV in western Ethiopia (n = 360), according to use of contraceptives, 2018.

![](pone.0237212.t001){#pone.0237212.t001g}

                                                                                     All women (N = 360)   Contraceptive users (N = 270\[75.0%\])   Non-users of contraceptives (N = 90\[25.0%\])                              
  ------------------------------------------------- -------------------------------- --------------------- ---------------------------------------- ----------------------------------------------- ------ ------------ ------ ---------
  Health facility                                   Hospitals                        216                   60.0                                     142                                             52.6   74           82.2   \<0.001
  Health centers                                    144                              40.0                  128                                      47.4                                            16     17.8                
  Age (years)[†](#t001fn002){ref-type="table-fn"}                                    31.7 (6.2)                                                     31.2 (5.7)                                             33.1 (7.4)          0.011
  Marital status                                    Married                          291                   80.8                                     239                                             88.5   52           57.8   \<0.001
  Unmarried                                         69                               19.2                  31                                       11.5                                            38     42.2                
  Residence                                         Urban                            338                   93.9                                     256                                             94.8   82           91.1   0.20
  Rural                                             22                               6.1                   14                                       5.2                                             8      8.9                 
  Schooling                                         No formal education              76                    21.2                                     61                                              22.6   15           17.1   0.67
  Primary education                                 186                              52.0                  136                                      50.4                                            50     56.8                
  Secondary Education                               69                               19.3                  52                                       19.3                                            17     19.3                
  Any post-secondary education                      27                               7.5                   21                                       7.8                                             6      6.8                 
  Missing                                           2                                                      0                                                                                        2                          
  Monthly family income                             Less than 1,500 Ethiopian Birr   188                   52.2                                     135                                             50.0   53           58.9   0.021
  ≥1,500 Ethiopian Birr                             160                              44.4                  129                                      47.8                                            31     34.4                
  Don't know                                        12                               3.3                   6                                        2.2                                             6      6.7                 
  Decision-regarding income                         Respondent                       141                   39.2                                     85                                              31.5   56           62.2   \<0.001
  Husband/partner/family                            87                               24.2                  68                                       25.2                                            19     21.1                
  Respondent and husband partner jointly            132                              36.7                  117                                      43.3                                            15     16.7                
  Travel time to health facility                    \<60 minutes                     285                   79.4                                     214                                             79.6   71           78.9   0.98
  60 to \<120 minutes                               40                               11.1                  30                                       11.2                                            10     11.1                
  ≥120 minutes                                      34                               9.5                   25                                       9.3                                             9      10.0                
  Missing                                           1                                                      1                                                                                        0                          
  Cost of travel (round trip)                       \<25 Ethiopian Birr              290                   80.8                                     220                                             81.8   70           77.8   0.15
  25 to \<50 Ethiopian Birr                         24                               6.7                   14                                       5.2                                             10     11.1                
  ≥50 Ethiopian Birr                                45                               12.5                  35                                       13.0                                            10     11.1                
  Missing                                           1                                                      1                                                                                        0                          

^‡^ Chi-square test used for categorical variables; t-test used for continuous variables.

^†^ Continuous variable, mean and standard deviation (SD) presented.

HIV-related, reproductive-related and HBM factors of sexually active women living with HIV {#sec017}
------------------------------------------------------------------------------------------

Results in [Table 2](#pone.0237212.t002){ref-type="table"} show the HIV-related, reproductive-related and HBM factors, with 111 (30.9%) women reporting that they learned of their HIV status 10 or more years ago. While all of the women were using ART (results not shown), 21.0% of them had been using ART for ten or more years. Overall, 77.2% had a CD4 cell count of greater than or equal to 350 with a mean of 611 cells/μL. Furthermore, 79.2% of women knew that their partner had been tested for HIV, of whom, 33.3% reported that their partner was HIV-negative. Only 14.5% did not have a child at home. Half of the women (48.5%) reported not having given birth since their HIV diagnosis. Among 152 recorded births given by the participants in the last five years, 17.8% were reported as mistimed births and 25.7% were reported as unwanted births. The conception of 129 (84.9%) births given by the participants were after learning of their HIV-positive result. The percentage of women who reported high perceived susceptibility to pregnancy (unintended) and severity of being pregnant while living with HIV were 20.8% and 30.7%, respectively. High perceived barriers and high perceived benefits were reported by 32.2% and 33.3% of participants, respectively. Finally, 33.3% reported high cues to action. There were significant differences between contraceptive users and non-users with respect to partner testing status, number of children living at home, number of children since HIV diagnosis, perceived susceptibility, perceived severity, perceived benefits and perceived barriers.

10.1371/journal.pone.0237212.t002

###### HIV-related, reproductive-related and HBM factors among sexually active women living with HIV in western Ethiopia according to use of contraceptives, 2018 (n = 360).

![](pone.0237212.t002){#pone.0237212.t002g}

  Characteristics                                                           Categories        All women (N = 360)   Contraceptive users (N = 270)   Non-users of contraceptives (N = 90)   p[‡](#t002fn001){ref-type="table-fn"}                 
  ------------------------------------------------------------------------- ----------------- --------------------- ------------------------------- -------------------------------------- --------------------------------------- ------ ------ -------------------------------------------
  Time since HIV diagnosis                                                  ≤ 5 years         125                   34.8                            91                                     33.8                                    34     37.8   0.61
  5 to \< 10years                                                           123               34.3                  96                              35.7                                   27                                      30.0          
  ≥10 Years                                                                 111               30.9                  82                              30.5                                   29                                      32.2          
  Missing                                                                   1                                       1                                                                      0                                                     
  Time since HIV diagnosis (in years)[†](#t002fn002){ref-type="table-fn"}                     7.2(3.9)                                                                                                                                           
  Time on ART                                                               ≤5 years          157                   43.9                            120                                    44.8                                    37     41.1   0.30
  5 to \< 10years                                                           126               35.2                  97                              36.2                                   29                                      32.2          
  ≥10 Years                                                                 75                21.0                  51                              19.0                                   24                                      26.7          
  Missing                                                                   2                                       2                                                                      0                                                     
  Time on ART (in years) [†](#t002fn002){ref-type="table-fn"}                                 6.2(3.6)                                                                                                                                           
  Health status since ART started                                           Poor/quite poor   1                     0.3                             0                                      0.0                                     1      1.1    0.43[††](#t002fn003){ref-type="table-fn"}
  Neither good nor poor                                                     9                 2.5                   7                               2.6                                    2                                       2.2           
  Quite good                                                                22                6.1                   16                              5.9                                    6                                       6.7           
  Very good                                                                 328               91.1                  247                             91.5                                   81                                      90.0          
  Recent CD4 count                                                          \< 350 cells/μL   78                    22.8                            58                                     22.7                                    20     23.3   0.91
  ≥350 cells/μL                                                             264               77.2                  198                             77.3                                   66                                      76.7          
  Missing                                                                   18                                      14                                                                     4                                                     
  CD4 (cells/μL) [†](#t002fn002){ref-type="table-fn"}                                         601.1 (298.6)                                                                                                                                      
  Partner tested for HIV                                                    Yes               282                   79.2                            221                                    82.8                                    61     68.5   0.016
  No                                                                        27                7.6                   17                              6.4                                    10                                      11.2          
  Don't know                                                                47                13.2                  29                              10.9                                   18                                      20.2          
  Missing                                                                   4                                       3                                                                      1                                                     
  HIV status of the partner (n = 282)                                       Negative          94                    33.3                            77                                     34.8                                    17     27.9   0.54
  Positive                                                                  185               65.6                  142                             64.3                                   43                                      70.5          
  Don't Know                                                                3                 1.1                   2                               0.9                                    1                                       1.6           
  Number of children living at home                                         No children       52                    14.5                            23                                     8.6                                     29     32.2   \<0.001
  1--2 children                                                             210               58.5                  164                             61.0                                   46                                      51.1          
  3 or more children                                                        97                27.0                  82                              30.5                                   15                                      16.7          
  Missing                                                                   1                                       1                                                                      0                                                     
  Number of children not currently living with mother at home               No children       274                   77.2                            207                                    77.5                                    67     76.1   0.69
  1 child                                                                   33                9.3                   26                              9.7                                    7                                       8.0           
  2 or more                                                                 48                13.5                  34                              12.7                                   14                                      15.9          
  Missing                                                                   5                                       3                                                                      2                                                     
  Intention of all births in the last five years (n = 152)                  Intended          86                    56.6                            82                                     57.3                                    4      44.4   0.46[††](#t002fn003){ref-type="table-fn"}
  Mistimed                                                                  27                17.8                  24                              16.8                                   3                                       33.3          
  Unwanted                                                                  39                25.7                  37                              25.9                                   2                                       22.2          
  HIV-status of the mother at conception (n = 152)                          HIV-negative      3                     2.0                             3                                      2.1                                     0      0.0    0.25[††](#t002fn003){ref-type="table-fn"}
  HIV-positive                                                              129               84.9                  123                             86.0                                   6                                       66.7          
  Unknown                                                                   20                13.2                  17                              11.9                                   3                                       33.3          
  Children born after learning HIV status                                   No children       174                   48.5                            105                                    39.0                                    69     76.7   \<0.001
  1 child                                                                   123               34.3                  105                             39.0                                   18                                      20.0          
  2--3 children                                                             62                17.3                  59                              21.9                                   3                                       3.3           
  Missing                                                                   1                                       1                                                                      0                                                     
  Perceived susceptibility                                                  Low               130                   36.1                            71                                     26.3                                    59     65.6   \<0.001
  Medium                                                                    155               43.1                  133                             49.3                                   22                                      24.4          
  High                                                                      75                20.8                  66                              24.4                                   9                                       10.0          
  Perceived severity                                                        Low               119                   33.8                            99                                     37.6                                    20     22.5   0.031
  Medium                                                                    125               35.5                  87                              33.1                                   38                                      42.7          
  High                                                                      108               30.7                  77                              29.3                                   31                                      34.8          
  Missing                                                                   8                                       7                                                                      1                                                     
  Perceived benefits                                                        Low               122                   34.2                            75                                     28.0                                    47     52.8   \<0.001
  Medium                                                                    120               33.6                  99                              36.9                                   21                                      23.6          
  High                                                                      115               32.2                  94                              35.1                                   21                                      23.6          
  Missing                                                                   3                                       2                                                                      1                                                     
  Perceived barriers                                                        Low               99                    33.3                            82                                     37.3                                    17     22.1   0.042
  Medium                                                                    99                33.3                  71                              32.3                                   28                                      36.4          
  High                                                                      99                33.3                  67                              30.5                                   32                                      41.6          
  Missing                                                                   63                                      50                                                                     13                                                    
  Cues to action                                                            Low               129                   36.4                            103                                    38.9                                    26     29.2   0.12
  Medium                                                                    107               30.2                  73                              27.6                                   34                                      38.2          
  High                                                                      118               33.3                  89                              33.6                                   29                                      32.6          
  Missing                                                                   6                                       5                                                                      1                                                     

^‡^ Chi-square test used for categorical variables; t-test used for continuous variables.

^†^ Continuous variable, mean and standard deviation presented.

^††^ Fisher exact test used.

Contraceptive use characteristics among sexually active women living with HIV {#sec018}
-----------------------------------------------------------------------------

Among sexually active WLHIV, 75% used contraception. Of the women who reported contraceptive use, injectables were the most commonly used method (44.8%), followed by condoms (37.4%) and implants (28.5%). For a better understanding of contraceptive use, mutually exclusive categories were created for short-acting and reversible contraceptive users; 15.0% used condoms only, 33.5% used short-acting only, and 28.6% used long-acting only. Dual users of condoms with short-acting contraception (pills or injectables) were 15.0% while dual users of condoms with long-acting contraception (IUDs or implants) were 7.9%. The primary source of accessing contraception was health centers (51.1%). Additionally, 60.4% of the participants were informed of the side effects of the contraceptive method they were using by a health or family planning worker (see [Table 3](#pone.0237212.t003){ref-type="table"}). Among women who were not using contraception, 64 (71.9%) had no intention of using contraception in the future (result not shown).

10.1371/journal.pone.0237212.t003

###### Selected contraceptive indicators among sexually active women living with HIV in western Ethiopia, 2018 (N = 270).

![](pone.0237212.t003){#pone.0237212.t003g}

  Variables                                                              Categories                    Frequency   Percent
  ---------------------------------------------------------------------- ----------------------------- ----------- ---------
  Contraceptive method used (multiple)                                   Condoms                       101         37.4
  Pills                                                                  8                             3.0         
  Injectables                                                            121                           44.8        
  IUDs                                                                   20                            7.4         
  Implants                                                               77                            28.5        
  Sterilization                                                          3                             1.1         
  Emergency contraception                                                1                             0.4         
  Categories of contraceptive used (n = 266)                             Condoms use only              40          15.0
  Short-acting only (pills, injectables)                                 89                            33.5        
  **Dual**: Condoms and short-acting (pills, injectables)                40                            15.0        
  Long-acting only (IUDs, implants)                                      76                            28.6        
  **Dual**: Condoms and long-acting (IUDs, implants)                     21                            7.9         
  Final decision on contraceptive selection                              You alone                     109         40.4
  Provider                                                               36                            13.3        
  Partner                                                                20                            7.4         
  You and provider                                                       39                            14.4        
  You and partner                                                        48                            17.8        
  You, partner and provider                                              18                            6.7         
  Partner support towards contraceptive use                              Supportive                    223         82.6
  Indifferent                                                            34                            12.6        
  Not supportive                                                         7                             2.6         
  Does not know I am using it                                            6                             2.2         
  The reason that the partner opposes contraceptive use (n = 7)          Wants to have more children   5           71.4
  Religion                                                               1                             14.3        
  Harms my health                                                        1                             14.3        
  Time on contraception                                                  12 months or less             74          27.6
  \>12 to 36 months                                                      124                           46.3        
  \>36 months                                                            70                            26.1        
                                                                         Missing                       *2*         
  Source of contraception                                                Hospital                      70          25.9
  Health center                                                          138                           51.1        
  Health post                                                            10                            3.7         
  Private-for-profit                                                     29                            10.7        
  Non-government organization                                            23                            8.5         
  Counselled on side effects                                             Yes                           163         60.4
  No                                                                     107                           39.6        
  If counselled, informed what to do concerning side effects (n = 163)   Yes                           157         96.3
  No                                                                     6                             3.7         
  Was informed on other contraceptive methods                            Yes                           165         61.1
  No                                                                     105                           38.9        
  Using the method of your choice                                        Yes                           258         95.6
  No                                                                     12                            4.4         

Predictors of contraceptive practice among sexually active women living with HIV {#sec019}
--------------------------------------------------------------------------------

Among the modifying/enabling factors, the prevalence of contraceptive use among women accessing health centers for ART was 1.25 times higher than women who accessed ART through hospitals (adjusted prevalence ratio \[APR\] = 1.25; 95%CI 1.10--1.42) (see [Table 4](#pone.0237212.t004){ref-type="table"}). Compared to women who reported not having any children after HIV diagnosis, having 2 or more children (APR = 1.31; 95%CI 1.09--1.58) after HIV diagnosis was also associated with increased risk of contraceptive use. The prevalence of contraceptive use among unmarried women was 0.69 times lower than their married counterparts (APR = 0.69; 95%CI 0.50--0.95).

10.1371/journal.pone.0237212.t004

###### Factors associated with contraceptive practice among sexually active women living with HIV in western Ethiopia, 2018 (n = 356).

![](pone.0237212.t004){#pone.0237212.t004g}

  Characteristics                           Categories        Contraceptive use   Unadjusted PR (95% CI)   Adjusted PR (95% CI)                                                 
  ----------------------------------------- ----------------- ------------------- ------------------------ ---------------------- ---------------------- ---------------------- -----
  **Modifying/enabling factors**                                                                                                                                                
  Health facility                           Hospitals         142                 52.6                     74                     82.2                   Ref                    Ref
  Health centers                            128               47.4                16                       17.8                   **1.35(1.17--1.57)**   **1.25(1.10--1.42)**   
  Marital status                            Married           239                 88.5                     52                     57.8                   Ref                    Ref
  Unmarried                                 31                11.5                38                       42.2                   **0.55(0.39--0.78)**   **0.69(0.50--0.95)**   
  Decision-making regarding income          Respondent only   85                  31.5                     56                     62.2                   Ref                    Ref
  Husband/partner/family                    68                25.2                19                       21.1                   **1.30(1.03--1.63)**   0.94(0.77--1.14)       
  Respondent and husband/ partner jointly   117               43.3                15                       16.7                   **1.47(1.21--1.78)**   1.18(0.99--1.41)       
  Number of children living at home         No children       23                  8.6                      29                     32.2                   Ref                    Ref
  1--2 children                             164               61.0                46                       51.1                   **1.77(1.17--2.67)**   1.25(0.87--1.80)       
  3 or more children                        82                30.5                15                       16.7                   **1.91(1.26--2.90)**   1.28(0.89--1.85)       
  Children born after learning HIV status   No children       105                 39.0                     69                     76.7                   Ref                    Ref
  1 child                                   105               39.0                18                       20.0                   **1.41(1.18--1.70)**   1.15(0.97--1.36)       
  2 or more children                        59                21.9                3                        3.3                    **1.58(1.32--1.88)**   **1.31(1.09--1.58)**   
  **Perception**                                                                                                                                                                
  Perceived susceptibility                  Low               71                  26.3                     59                     65.6                   Ref                    Ref
  Medium                                    133               49.3                22                       24.4                   **1.57(1.26--1.96)**   **1.55(1.28--1.87)**   
  High                                      66                24.4                9                        10.0                   **1.61(1.28--2.04)**   **1.49(1.20--1.86)**   
  Perceived benefits                        Low               75                  28.0                     47                     52.8                   Ref                    Ref
  Medium                                    99                36.9                21                       23.6                   **1.34(1.08--1.66)**   1.16(0.97--1.39)       
  High                                      94                35.1                21                       23.6                   **1.33(1.07--1.65)**   1.11(0.91--1.35)       

Adjusted for for health facility, marital status, decision-making regarding income, number of children living at home, perceived benefits, children born after learning HIV status, and perceived susceptibilities.

After adjusting for health facility, marital status, decision-making regarding income, number of children living at home, perceived benefits, and children born after learning HIV status, women with both high (APR = 1.49; 95%CI 1.20--1.861) and medium (APR = 1.55; 95%CI 1.28--1.87) perceived susceptibilities were more likely to utilize contraception compared to those with low perceived susceptibility.

Discussion {#sec020}
==========

Using the HBM, this study examined contraceptive practices in Ethiopia among sexually active WLHIV aged 18--49 years who reported being fecund and not wanting children within two years. Three-quarters of this population were using some form of contraception, which serves as a crucial step in pursuing reproductive goals as well as supporting the PMTCT programs by preventing unintended pregnancies \[[@pone.0237212.ref044]\]. However, we found that a quarter of the participants had unmet contraceptive needs, which requires further intervention. It was also demonstrated that prevalence of contraceptive use was significantly lower among unmarried women compared to married women, which could put sexually active unmarried WLHIV at increased risk of unintended pregnancies. However, accessing health centers for ART as well as a higher number of children being born after HIV diagnosis were associated with increased risk of contraceptive use. Interestingly, perceived susceptibilities regarding conception were significantly associated with increased risk of contraceptive use.

Despite the high rate of contraceptive use, the high prevalence of mistimed (17.8%) and unwanted births (25.7%) over the 5-year period, as well as the high unmet need for contraception at the time of data collection (25.0%), raises concerns about efficacy, accessibility, and utilization of contraception among WLHIV \[[@pone.0237212.ref009]\]. A cross-sectional study at Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia also showed similar magnitude of unmet needs for contraception among married WLHIV (25.1%) \[[@pone.0237212.ref045]\]. Two-thirds of WLHIV who had an unmet need for contraception had no intention of using contraception in our study, which was consistent with a finding from Uganda (77.6%) \[[@pone.0237212.ref046]\]. Improving awareness and counselling regarding effective contraception is thus important. Moreover, improving the quality of contraceptive programs \[[@pone.0237212.ref047]\] could have a high impact on addressing unmet needs for contraception and unintended pregnancy.

Importantly, different contraceptive methods are available in Ethiopia: pills, condoms, injectables, implants, IUDs, vasectomy and tubal ligation. Our finding that showed 37.4% of contraceptive users used condoms (with 15% using it as their sole method of contraception) is consistent with a prior study in Addis Ababa, Ethiopia \[[@pone.0237212.ref019]\]. The use of condoms offers HIV prevention. However, reliance on condoms as a single contraceptive choice is suboptimal for pregnancy prevention (at 18% failure rate under typical use conditions) \[[@pone.0237212.ref017], [@pone.0237212.ref048]\]. Therefore, ensuring highly effective contraceptive use while addressing concerns related to HIV is an excellent opportunity to meet the reproductive goals of WLHIV.

Despite dual methods providing the best protection against both pregnancy and sexually transmitted infections (STIs)/HIV \[[@pone.0237212.ref017]\], only about a quarter of participants were using dual methods (7.9% used condoms with long-acting contraception and 15% with short-acting contraception). This finding was lower than that reported in a study from South Africa (33%) \[[@pone.0237212.ref049]\]. The high prevalence of STIs among WLHIV (16.3%) \[[@pone.0237212.ref050]\], as well as the many WLHIV who are unaware of the HIV status of their partner (7.6% reported their partner was not tested and 13.2% reported they did not know whether or not their partner had been tested) and the high rate of serodiscordance (HIV-negative partner) in our study creates additional health concerns for PLHIV. This reinforces the need for more support regarding dual use of contraception both in HIV clinics and family planning clinics.

Among hormonal contraception, injectables were the most commonly used method. This conforms to a prior study conducted in Addis Ababa, Ethiopia \[[@pone.0237212.ref019]\]. In our study, the second most used hormonal contraception was implants (28.5%). Injectables and implants were also the most accepted methods among the general population of Ethiopia \[[@pone.0237212.ref035]\] although these methods are thought to interact with some ART drugs. This raises concern around reduced effectiveness of injectables and implants methods \[[@pone.0237212.ref015], [@pone.0237212.ref051]\]. Compared to implants, injectables have a higher failure rate under typical use conditions \[[@pone.0237212.ref017]\]. Moreover, the adoption of IUDs was very low in our study, which might be because of misconceptions, such as negative perceptions by healthcare providers regarding its safety, negative perceptions towards IUD provision for nulliparous women and WLHIV, as well as low knowledge of IUDs \[[@pone.0237212.ref052]\]. Dispelling misinformation about IUDs and ensuring when WLHIV can use it safely would therefore be helpful. Importantly, women who wish to limit childbirth or want long-term protection should be supported by receiving appropriate counselling on the safety and efficacy of long-acting contraception of their choice. It is also crucial to meet contraceptive needs that align with their changing fertility intention.

Importantly, some modifying and enabling factors were associated with contraceptive use. Women accessing ART at health centers were more likely to use contraception compared to women accessing ART at hospitals. This is concerning given that more contraceptive choices are available in hospitals. In our study, the majority of contraceptive users reported that they obtained their contraceptive methods from health centers. Given health centers are available closer to the community (distance), WLHIV might be more likely to obtain contraception from the health centers as hospitals are usually further away \[[@pone.0237212.ref053]\]. Enhancing quality counselling is crucial given that only about half of contraceptive users reported being counselled on contraceptive side effects and on what to do if side effects develop. This echoes findings in Addis Ababa, Ethiopia \[[@pone.0237212.ref054]\]. Taken together, our study highlights the importance of enhancing the quality of contraceptive information, counselling and services in HIV clinics as well as family planning clinics at all levels of health facilities.

Our findings reveal significant differences in the prevalence of contraceptive use between married and unmarried sexually active WLHIV, which raises concerns about unmarried women's access to contraception. This finding is supported by a study in Ethiopia, which showed that unmarried women were also more likely to experience unintended pregnancies \[[@pone.0237212.ref022]\] and abortion \[[@pone.0237212.ref055]\] compared to married women. Enhancing access to and utilization of contraceptive information and confidentiality is important because unmarried women might face judgmental attitudes regarding their reproductive options \[[@pone.0237212.ref056]\]. Providing important support and contraceptive provisions that consider the circumstances of sexually active unmarried women could bridge this gap.

The prevalence of contraceptive use among WLHIV who had two or more children since HIV diagnosis was 1.31 times higher than WLHIV who never had a child after HIV diagnosis. Challenges during previous pregnancy such as HIV-related stigma from health professionals \[[@pone.0237212.ref057]\], distress and fear related to maternal and child health, personal shame associated with being pregnant as a WLHIV, and uncertainty about the future of the unborn baby \[[@pone.0237212.ref058]\], might be reasons not to consider another pregnancy. Essentially, these underscore the need for appropriate reproductive strategies, both conception strategies and contraception. Given number of children living at home and age were not significantly associated with contraceptive use among sexually active WLHIV in our study, further investigation using a larger study may be able to better examine the impact of number of children and age on contraceptive practice.

Our study found that women's high, as well as medium perceived susceptibilities towards unintended pregnancy had a substantial impact on contraceptive use compared with low perceived susceptibility. The perceived susceptibilities assessed the perceived chance of pregnancy (unintended) if contraception is not used. Given understanding susceptibilities motivate women to practise contraception, healthcare providers should incorporate these perceptions to guide counselling and education while supporting safer conception for those who wish to have a child.

Despite only showing an association in an unadjusted model, the effect of perceived benefits cannot be excluded. Women with a high perception about the benefits of contraceptive use had an increased risk of contraceptive use compared to women with a low perceived benefits (in an unadjusted model). Essentially, contraceptive counselling regarding long-term protection of contraception, convenience of methods, effectiveness, as well as dual protection might increase adherence \[[@pone.0237212.ref059]\] and uptake of contraceptive use \[[@pone.0237212.ref060]\]. Improving cultural acceptability and community opinion towards contraception may also enhance contraceptive use \[[@pone.0237212.ref061]\]. Furthermore, developing contraceptive counselling guidelines and policies based on the HBM would be valuable in supporting WLHIV to achieve their reproductive goals. It is also essential to understand more about the acceptability of side effects and issues related to specific methods. Furthermore, the perceived benefits should be seen in relation to perceived barriers. The contraceptive initiation often requires targeted interventions of improving benefits while reducing barriers. Indeed, our current study adds evidence to previous studies \[[@pone.0237212.ref027]--[@pone.0237212.ref030]\] that show that the HBM can provide crucial insights into individual behaviours that improve contraceptive practice.

Strengths and limitations {#sec021}
-------------------------

A major strength of the study was that the study applied the HBM and examined contraceptive use among all sexually active WLHIV not just those in union or married. However, this study must be considered in light of some limitations. First, unmarried women might be reluctant to report recent sexual activity in Ethiopia due to the sensitivity of the questions and social desirability bias. Therefore, a few sexually active unmarried WLHIV might have been excluded from the analysis. Second, all the data were self-reported, which is subject to recall bias. However, the data were collected using a standardized questionnaire by experienced female data collectors who had never worked at the selected HIV clinics to minimize biases. Third, we cannot infer associations described to causality because of the cross-sectional nature of the data.

Conclusion {#sec022}
==========

The majority of sexually active WLHIV in our study were using contraception, which gives insights into the role contraception plays in meeting family planning goals as well as in supporting PMTCT programs. Despite this, our findings also suggest the need for ongoing counselling and access to effective contraception given the rate of unmet needs for contraception and unintended pregnancies. Further interventions are required to address factors that impede the use of contraception when WLHIV do not want to conceive, particularly in terms of increasing the uptake of highly effective contraception because of lower efficacy of some of the methods (e.g., condom use only). The concepts within the HBM could shape contraceptive counselling for the identified 'at risk' women to achieve their reproductive goals as well as prevent mother to child transmission of HIV although this might require further investigation using an interventional study. Our findings also suggest the HBM would be a valuable resource for healthcare providers, program planners and policymakers to develop guidelines and policies for contraceptive counselling and choices.

We would like to thank study participants and data collectors for making this research successful. We would also like to thank Natalia Soeters for language proof.
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16\. Table 1: This is stylistic, but it is easier for the eye if the n and % are near each other (so n is right aligned and % is left aligned)

17\. Table 1: The first foot note doesn't seem to actually appear in the table? Also footnotes should read left to right, top to bottom, so the other footnote should be switched.

18\. Line 239: Should be "reporting"

19\. Line 248: You should restate what susceptibility and severity are referring to

20\. Lines 270-282: Referring back to my comment above about your statistical approach, this way of reporting is a bit confusing. If the ones you report as unadjusted did not remain significant in the final model, this should be stated.

21\. Lines 285-299: This final section is descriptive and would make more sense to be presented earlier.

Discussion

22\. Lines 314-315: How does the prevalence of unmet need found in your study compare to that found in other studies?

23\. Line 333-335 "There is considerable evidence that utilizing pre-exposure prophylaxis (although not currently available in Ethiopia) could address some of the gaps related to HIV transmission among non-condom users \[40\]" This does not seem particularly relevant considering your population is living with HIV. Since this paper is very lengthy it would be better to stick with things relevant to your findings.

24\. Line 361: This is repetitive

25\. Line 362-364: Wording unclear

26\. Line 382-383 "were about fourteen times more likely to use contraception compared to women who never had a child after HIV diagnosis" You should acknowledge here that you had an extremely small sample size and wide confidence intervals for this finding.

27\. Lines 383-388: It seems like this would be the expected outcome, as women with more children are probably less likely to want more children and are likely older. Did you consider this, or look at this at all in your data? Seems like a more simple explanation than the ones listed here.

28\. Line 391: "This perception evaluated the chance of unintended pregnancies." It's not clear to me what this means.

29\. Line 396: It's unclear to me what "ruled out" means in this context.

30\. Line 398: I think the "perceived susceptibility" here should be perceived benefit?

31\. Lines 399-402: "Essentially, improved perceptions regarding contraception such as long-term protection, convenience of methods, effectiveness as well as dual protection for these women are critical factors identified by the HBM in our study and might increase uptake of contraception." Did your findings really support this? How do you interpret the finding that most of your "HBM factors" did not appear in your final model?

Reviewer \#2: Reviewer's report

Title: Contraceptive use among sexually active women living with HIV in western Ethiopia

Version: 1

Date: 21 January 2020

Reviewer's report:

Thank you for the opportunity to review the manuscript entitled "Contraceptive use among sexually active women living with HIV in western Ethiopia by Feyissa et al. on a very important subject. This is a well- written manuscript that is grounded in the Health Belief Model with clear objective and well written introduction. The methods are sound. The results are adequately presented and well synthesized against previous evidence and the model adapted as the conceptual framework. The authors also acknowledged the weaknesses/limitations in their study. Their conclusions are consistent with the evidence and arguments presented and addressed the main question posed. I strongly believe this manuscript makes a meaningful contribution to the field of public health and therefore, should be considered for publication pending editor\'s decision.

Nonetheless, these are few suggestions, which I think could strengthen the paper before publication.

Abstract

1\. This is a well written abstract. However the authors can add a brief background to the abstract.

2\. Line 21 Please specify the exact date (e.g 1st March to 1st June 2018)

3\. Line 29 should read... were associated with increased "odds of" contraceptive practice.

4\. Line 41, keywords: Health belief should be "health belief model"

Introduction

5\. Very good introduction with adequate review of literature. However, this can be more strengthened when discussed within the context of the SDGs. Specifically goal 3.3

6\. Line 63-64, can you please specify some of these studies?

Conceptual framework

7\. Please this is a very minor comment. I would suggest the authors bring a sub-heading "conceptual framework" and also provide a diagrammatical representation of the variables considered in the model and how they are related to the outcome variable (s).

Materials and Methods

8\. Line 98 should be read "Materials and Methods"

9\. Is it possible to provide a map indicating the study settings?

10\. Can you provide a sample of the instrument used for the data collection as an attachment (supplementary file)?

11\. Line 101 can you please specify the exact date?

12\. From Figure 1, the total women surveyed are 1082. Was this the total number of HIV positive women attending HIV clinics across the 4 facilities you were able to reach? If yes, how many were in each facility? How did you ensure representativeness across the facilities?

13\. Although you have given a very nice flow of the way the 360 sample was arrived at but kindly explain how the systematic random sampling was used to arrive at the unit of analysis.

14\. Line 119, please where was the piloting done? and what informed the choice of that place for the piloting? How many WLHIV were used for the piloting?

15\. Line 122, please how long were the nurses trained and on what?

16\. Line 169-170, please how was data on CD4 counts collected, self reported?? or from their records?? this should be acknowledged at the discussion section?

17\. Line 203-205, please what informed the categorization of the "susceptibility" into tertiles (example: high susceptibility, medium susceptibility and low susceptibility?

18\. Statistical analyses.

a\. Please how was the adjustment done? (see Table 3).

b\. Please what informed the choice of the reference categories?

c\. Kindly specify how the missing values were treated at the inferential analysis stage.

Results

19\. I suggest you bring the Table 4 (Selected contraceptive indicators among sexually active women with HIV in western Ethiopia, 2018) before Table 3 (Factors associated with contraceptive practice among sexually 283 active women living with HIV in western Ethiopia, 2018) to make all the descriptive results come before the inferential results(logistic regression).

Discussion

20\. Line 304, the sentence... "supporting the PMTCT programs by preventing unintended pregnancies" should be supported with evidence

21\. The authors have done an excellent job by acknowledging the weaknesses of their study including the study design, however, they did not acknowledge the strength of their study. I also suggest this should be given a sub-heading for easy reading.

Conclusion

22\. Well written conclusions emanating from the study's findings. Despite this can you please bring a subheading "conclusions and policy implications" directly after the strength and weaknesses of the study to make it easy for readers who wish to go to the conclusion section directly do that at ease.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237212.r002
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8 Jul 2020

PONE-D-19-30290R1

Contraceptive use among sexually active women living with HIV in western Ethiopia

PLOS ONE

Dear Dr. Feyissa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 22 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Zelalem T. Haile, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Additional Editor Comments (if provided):

I am happy to inform you that it is provisionally accepted for publication pending your response to the minor points made by the review. Therefore, I invite you to respond to these comments and revise your manuscript accordingly. A rapid response on your part will facilitate a prompt publication process.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: No

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors to a greater extent have addressed all my major concerns. Therefore, pending Editors decision, the manuscript should be accepted for publication.

Reviewer \#3: Review of contraceptive use among sexually active women living with HIV in western Ethiopia

Thank you for the opportunity to review this paper which reviewed contraceptive use among sexually active women living with HIV. The researchers found that contraceptive use amongst sexually active WLHIV was found to be high compared to previous studies. WLHIV having two or more children after HIV diagnosis and with high and medium perceived susceptibility towards unintended pregnancy were more likely to use contraception. However, unmarried women were less likely to use contraception.

This paper is well written. Please find some minor editions from attached documents

Kind regards,

Reviewer \#4: Remarks to the Authors

The manuscript entitled as "Contraceptive use among sexually active women living with HIV in western Ethiopia" is a research study that was conducted among sexually active women living with HIV in Ethiopia. This is an interesting study aimed at examining contraceptive practice among sexually active women living with HIV and identify the factors that influenced such practice using the Health Belief Model. Overall the study is clear and the results are consistent with the aim of the study. However, I recommend the following minor changes for the manuscript.

Introduction

1\. The Introduction is well organized. However, the concepts described in the introduction are numerous, can be shortened for clarity.

2\. Line 49- better to write it as 'World health organization (WHO)'

Materials and methods

1\. Line 102- Better to remove the sentence on line 102. 'Nekemte and Gimbi are the capitals of the respective zones.'

References

1\. The reference lists should be re-checked for clarity. E.g. Ref - 17, and 18.

2\. Write in full words abbreviations/acronyms used in reference lists. E.g. Ref - 1, 2, and 3.

3\. Write in small letter. Ref. 4.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237212.r004

Author response to Decision Letter 1

9 Jul 2020

Dear Dr Zelalem T. Haile

Thank you for considering our recent manuscript "Contraceptive use among sexually active women living with HIV in western Ethiopia". We greatly appreciate the effort and comments from the reviewers.

In response to your letter dated July 08, 2020 regarding our manuscript, we would like to provide the following clarifications and amendments. We have attached both a clean and annotated version of the revised manuscript.

Reviewer \#2

The authors to a greater extent have addressed all my major concerns.

Therefore, pending Editors decision, the manuscript should be accepted for publication.

Response: Thank you for your time in reviewing the previous and current versions of our manuscript. The comments were very helpful.

Reviewer \#3

Review of contraceptive use among sexually active women living with HIV in western Ethiopia.

Thank you for the opportunity to review this paper which reviewed contraceptive use among sexually active women living with HIV. The researchers found that contraceptive use amongst sexually active WLHIV was found to be high compared to previous studies. WLHIV having two or more children after HIV diagnosis and with high and medium perceived susceptibility towards unintended pregnancy were more likely to use contraception. However, unmarried women were less likely to use contraception.

This paper is well written. Please find some minor editions from attached documents

Kind regards,

Response: We have amended the manuscript as per your editions.

Reviewer \#4

The manuscript entitled as "Contraceptive use among sexually active women living with HIV in western Ethiopia" is a research study that was conducted among sexually active women living with HIV in Ethiopia. This is an interesting study aimed at examining contraceptive practice among sexually active women living with HIV and identify the factors that influenced such practice using the Health Belief Model. Overall the study is clear and the results are consistent with the aim of the study. However, I recommend the following minor changes for the manuscript.

Introduction

1\. The Introduction is well organized. However, the concepts described in the introduction are numerous, can be shortened for clarity.

Response: We have edited for clarity and reduced the length of the introduction section.

2\. Line 49- better to write it as 'World health organization (WHO)'

Response: As per the comment, we have amended the statement and reads, 'The 2015 World Health Organization (WHO) guideline states there should be no criterion barrier in the initiation of antiretroviral therapy (ART) \[4\] which will help in reductions in HIV-related morbidity and mortality \[5\]'.

Materials and methods

1\. Line 102- Better to remove the sentence on line 102. 'Nekemte and Gimbi are the capitals of the respective zones.'

Response: We have deleted the statement.

References

1\. The reference lists should be re-checked for clarity. E.g. Ref - 17, and 18.

2\. Write in full words abbreviations/acronyms used in reference lists. E.g. Ref - 1, 2, and 3.

3\. Write in small letter. Ref. 4.

Response: As per the suggestions, we have amended the references.

10.1371/journal.pone.0237212.r005
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PONE-D-19-30290R2

Dear Dr. Feyissa,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Zelalem T. Haile, PhD

Academic Editor

PLOS ONE
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Contraceptive use among sexually active women living with HIV in western Ethiopia

Dear Dr. Feyissa:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Zelalem T. Haile

Academic Editor

PLOS ONE
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